Status | Study |
NOT_YET_RECRUITING |
Study Name: Phase 3 Study of ALXN1850 in Treatment-Na�ve Pediatric Participants With HPP Condition: Hypophosphatasia Date: 2023-10-06 Interventions: Participants will receive a ALXN1850 via subcutaneous (SC) injection. |
NOT_YET_RECRUITING |
Study Name: Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa Condition: Hypophosphatasia Date: 2023-10-06 Interventions: ALXN1850 will be administered via subcutaneous (SC) injection. |
NOT_YET_RECRUITING |
Study Name: Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa Condition: Hypophosphatasia Date: 2023-10-06 Interventions: ALXN1850 will be administered via subcutaneous (SC) injection. |
Active, not recruiting |
Study Name: Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) Condition: Hypophosphatasia Date: 2016-05-23 Interventions: Drug: Asfotase alfa Other Name: Strensiq |
Not yet recruiting |
Study Name: Characterisation of Adult-Onset Hypophosphatasia Condition: Hypophosphatasia Date: 2016-05-04 Interventions: Other: no intervention - observational study |
Not yet recruiting |
Study Name: Health Burden of Hypophosphatasia Condition: Hypophosphatasia Date: 2016-04-01 Interventions: Other: no intervention |
Recruiting |
Study Name: Biomarker for Hypophosphatasia Disease Condition: HEREDITARY DISEASES METABOLISM, INBORN ERRORS Date: 2015-11-10 |
Completed |
Study Name: Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan Condition: Hypophosphatasia Date: 2015-08-11 Interventions: Biological: Asfotase Alfa Other Name: Strensiq |
Approved for marketing |
Study Name: Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) Condition: Hypophosphatasia Date: 2015-07-08 Interventions: Biological: asfotase alfa Patients participating in this program will receive 6 mg/kg/week asfotase alfa |
Completed |
Study Name: Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) Condition: Hypophosphatasia Date: 2015-03-26 Interventions: Drug: Asfotase Alfa (ALXN1215) Other Name: ALXN1215 |